Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belantamab mafodotin + GSK3174998
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Belantamab mafodotin + GSK3174998 is an investigational **combination therapy** for relapsed/refractory multiple myeloma, currently being studied in clinical trials. **Belantamab mafodotin** (BLENREP, also known as GSK2857916) is an antibody-drug conjugate (ADC) consisting of a humanized anti–B-cell maturation antigen (BCMA) monoclonal antibody linked to mafodotin, a microtubule inhibitor. This ADC targets BCMA on malignant plasma cells, delivering mafodotin to induce cytotoxicity, and stimulates immunogenic cell death with additional immune-mediated anti-tumor effects such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). **GSK3174998** is a fully human monoclonal antibody acting as an agonist of OX40 (CD134), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immune responses by increasing T-cell activation and proliferation. The rationale for the combination is to potentiate the immunomodulatory and cytotoxic effects in multiple myeloma by simultaneously targeting tumor cells and stimulating immune effector cells[1][3].
- Other names
- belamaf
02
Targets
BCMA (B-cell maturation antigen)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on belantamab mafodotin + GSK3174998.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belantamab mafodotin + GSK3174998.